Randomized, placebo‐controlled, double‐blind glycemic control trial of novel sodium‐dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus

AIMS/INTRODUCTION: In the present dose–response study, we evaluated the efficacy and safety of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium‐dependent glucose cotransporter 2, in Japanese patients with type 2 diabetes mellitus. MATERIALS AND METHODS: A total of 361 patients from...

Descripción completa

Detalles Bibliográficos
Autores principales: Kashiwagi, Atsunori, Kazuta, Kenichi, Yoshida, Satoshi, Nagase, Itsuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley-Blackwell 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210070/
https://www.ncbi.nlm.nih.gov/pubmed/25411597
http://dx.doi.org/10.1111/jdi.12156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210070/
https://www.ncbi.nlm.nih.gov/pubmed/25411597
http://dx.doi.org/10.1111/jdi.12156

Ejemplares similares